TLPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
TALPHERA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.08+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $81.57M
- P/E (TTM)
- –
- Dividend yield
- –
TALPHERA, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q2 25 | Q1 25 | Q3 24 | Q2 24 | Q1 24 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | – | – | – | – | – | – | – | – | – | $252.00K | $507.00K | $570.00K | – | – |
| Contract and Other Collaboration [Member] | – | – | – | – | – | – | – | – | – | $0 | $0 | $0 | – | – |
| DSUVIA [Member] | – | – | – | – | – | – | – | – | – | $224.00K | $478.00K | $444.00K | – | – |
| DZUVEO [Member] | – | – | – | – | – | – | – | – | – | $28.00K | $29.00K | $126.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Talphera's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.